Skip to contentP
Perspective Therapeutics, Inc.
P
CATXPerspective Therapeutics, Inc. Q2 2017 · 10-Q
Revenue$1.03M$1.03M−13.5% vs Q2 2016 Net Income-$1.45M-$1.45MN/M vs Q2 2016 EPS Diluted-$0.03-$0.03N/M vs Q2 2016 The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Perspective Therapeutics, Inc. · CIK 728387 · Engraved from SEC EDGAR
Operating Cash Flowderived-$1,661,000N/M Free Cash Flowderived-$1,753,000N/M Margins · derivedGross margin-0.1%−2.6 pt vs Q2 2016
Operating margin-143.9%−25.3 pt vs Q2 2016
Net margin-141.1%−30.7 pt vs Q2 2016
ended Dec 31, 2016 · filed Feb 9, 2017 · 40 d after period end